AI Is Compressing Pharma’s Information Layer, Not Replacing the Industry

Pharma and biotech look, at first glance, like ideal AI targets.

They generate huge volumes of data. They run repetitive documentation and compliance workflows. They rely on pattern recognition in chemistry, biology, genomics, safety, and clinical operations. And they spend enormous amounts of money trying to shorten time-to-decision.

That is exactly why AI is moving so fast here.

But the deeper story is more specific. AI is not replacing pharma evenly. It is hitting the industry hardest where work is structured, text-heavy, analysis-heavy, and rule-bound. It is much weaker where work still depends on experimental interpretation, regulatory strategy, safety accountability, wet-lab execution, or cross-functional scientific judgment.

The source assessment from March 24, 2026 covers 62 roles and shows a heavily polarized labor map: only 1 role reaches the near-fully-automated tier, 24 are in the heavy-assistance band, 36 stay in the limited-assistance band, and only 1 sits below 30%. That distribution matters because it shows the sector is not being hollowed out from a single end. It is being re-layered around AI across discovery, trials, safety, manufacturing, and commercialization.

The Market Is Massive, and the AI Layer Is Growing Much Faster Than the Base Industry

The source places the global pharmaceutical market at roughly $1.74-1.77 trillion in 2025, rising toward $1.84-1.88 trillion in 2026. Against that base, the AI submarkets are still smaller but growing faster:

  • AI drug discovery at roughly $2.9-6.9 billion in 2025
  • AI clinical trial tooling around $1.3 billion in 2024
  • AI pharmacovigilance around $600 million in 2024
  • a projected pharma AI market around $25.7 billion by 2030

The industry signals are also strong. The source file cites:

  • 75% of pharmaceutical companies treating GenAI as a strategic priority,
  • 91% of life-science executives recognizing AI value,
  • only 21% already in scaled deployment,
  • but roughly 75% already using, testing, or exploring AI in some form.

That combination matters. Pharma is not at universal production scale yet, but it has clearly moved beyond curiosity.

The Cleanest Rule in Pharma Is This: The More Structured the Workflow, the Higher the Exposure

The most exposed roles in the source are all roles where work can be broken into clean, machine-readable units:

  • adverse-event intake,
  • clinical data handling,
  • regulatory document assembly,
  • safety coding,
  • signal detection,
  • genomics pipelines,
  • warehouse management,
  • screening,
  • and heavily templated medical writing.

That is why the report’s highest-exposure jobs are not principal scientists or regulatory strategists. They are the people sitting inside repetitive information and workflow loops.

The highest-exposure roles in the study

Role Estimated AI replacement rate Why exposure is high
Adverse Event Reporting Specialist 90% Intake, coding, formatting, and submission are highly structured
Clinical Data Manager 75% Database cleaning, reconciliation, and query management are increasingly automated
High-Throughput Screening Specialist 70% Robotics plus algorithmic screening replace repetitive execution
Sterile Production Operator 70% Regulatory pressure and automation push manual aseptic work downward
Pharmacovigilance Specialist 70% Case processing is already moving toward touchless workflows
CTD/eCTD Writer 70% Document assembly and regulatory formatting are highly template-driven
Genomics Data Analyst 70% Standard pipeline work is increasingly automatic

These roles all sit where pharmaceutical work becomes data operations.

Pharmacovigilance Is the Closest Thing Pharma Has to True AI Automation

If there is one function where the case for replacement is already operational rather than theoretical, it is pharmacovigilance.

The source file points to Oracle Argus Safety, ArisGlobal LifeSphere, Veeva Vault Safety, and related systems as evidence that safety-case handling is becoming deeply automated. That includes:

  • intake,
  • classification,
  • MedDRA coding,
  • narrative drafting,
  • E2B formatting,
  • routing,
  • and increasingly multilingual ingestion.

This explains why the source assigns:

  • 90% to the adverse event reporting specialist,
  • 70% to the PV specialist,
  • 65% to the signal detection analyst,
  • but only 35-40% to higher-order safety science and risk-management roles.

AI is excellent at turning safety work into structured case flow. It is much weaker at the parts that still require clinical interpretation: causality judgment, label impact, signal significance, or regulatory posture after a safety event emerges.

So the safety stack is not disappearing. It is separating into two layers:

  1. machine-run intake and processing,
  2. human-run medical judgment and accountability.

Clinical Operations Are Being Rebuilt Around Fewer People and Better Systems

Clinical trials show the same pattern. The source notes that AI already helps with:

  • site selection,
  • patient matching,
  • monitoring prioritization,
  • data cleaning,
  • operational forecasting,
  • and document generation.

That is why:

  • the clinical data manager reaches 75%,
  • the CRA/monitor reaches 60%,
  • the recruitment specialist reaches 65%,
  • but the CTM holds at 30%,
  • and the clinical statistician stays lower at 40%.

The difference is not whether a role is “clinical.” It is whether the work is workflow-heavy or decision-heavy.

A CTM still manages timelines, vendors, escalation paths, and risk tradeoffs across multiple actors. A statistician still has to defend design choices and analytical logic under regulatory scrutiny. But a large share of data cleanup, remote monitoring, and patient-search work is now exposed because it is process work first and judgment work second.

Medical Writing Is Not Disappearing, but It Is No Longer a Pure Drafting Job

The source places the medical writer at 65% replacement risk. That is one of the clearest labor signals in the entire report.

The reason is simple. Modern LLM systems are already strong at:

  • drafting structured summaries,
  • turning TLF outputs into first-pass text,
  • assembling recurring sections of CSRs and IBs,
  • and managing consistency across templated submission components.

That does not eliminate the writer. But it changes the job. The writer becomes less of a first-draft producer and more of an editor, reviewer, factual controller, and regulatory-quality gatekeeper.

This is a broader pattern across pharma. AI is not killing the function. It is moving value upward inside the function.

Drug Discovery Sees Heavy AI Leverage, but the Wet-Lab Barrier Still Matters

Drug discovery is where AI gets the most attention, and for good reason.

The source points to:

  • AI-designed and AI-optimized molecules,
  • Recursion-Exscientia as an end-to-end platform case,
  • Schrödinger validating AI-enabled physics-driven design in late-stage programs,
  • Insilico Medicine pushing AI-discovered programs into human trials,
  • and AI-assisted protein engineering, CRISPR design, and genomic analysis.

That is why some discovery-side roles rise sharply:

  • lead optimization specialist at 65%,
  • protein engineer at 60%,
  • computational biologist at 60%,
  • cheminformatics specialist at 65%,
  • bioinformatician at 65%.

But exposure does not equal full substitution.

The source still keeps:

  • pharmacologists at 35%,
  • toxicologists at 35%,
  • formulation scientists at 30%,
  • cell biologists at 30%,
  • immunologists at 30%,
  • and gene-therapy researchers at 35%.

That split is telling. AI is strongest in candidate generation, ranking, prediction, and computational prioritization. It is weaker where science becomes messy, biological, multi-factor, and experimentally fragile.

Manufacturing Is Moving Fastest Where Regulation and Automation Align

Pharma manufacturing shows one of the most interesting combinations in the report: high technical feasibility, but uneven deployment because of validation and compliance burden.

The most exposed manufacturing and operations roles include:

  • sterile production operator at 70%,
  • GMP production operator at 60%,
  • cold-chain specialist at 60%,
  • warehouse manager at 65%,
  • cell-therapy production specialist at 60%.

The strongest example is sterile and cell-therapy manufacturing. The source cites Multiply Labs cutting CAR-T production cost by 74%, from roughly $100K+ to around $25K per dose, while massively improving space efficiency. That is not a software convenience. It is a manufacturing model shift.

But even here, full replacement is limited by:

  • GMP validation,
  • exception handling,
  • material variability,
  • cleaning and release logic,
  • and the need for human oversight in high-risk production environments.

So pharma manufacturing is not a story of “lights out” fully autonomous plants everywhere. It is a story of selective automation under regulatory constraint.

Regulatory Affairs Gets Faster, but Strategy Remains Human

Regulatory work also splits into two very different labor categories.

The source file assigns higher exposure to:

  • RA specialists,
  • CTD/eCTD writers,
  • document-heavy compliance roles,
  • and repeatable registration tasks.

But it keeps lower exposure for:

  • regulatory affairs managers,
  • FDA/EMA/NMPA strategic advisors,
  • market-access leaders,
  • and high-level regulatory consultants.

That distinction matters. AI can help draft, map requirements, compare precedents, and structure submission modules. It cannot yet reliably own the strategic layer:

  • Which filing path should be chosen?
  • What should be conceded versus defended with a regulator?
  • How should a safety signal or chemistry issue be framed across markets?
  • When should a company delay submission rather than force a weak package through?

That is not a formatting problem. It is a judgment problem.

The New High-Leverage Jobs Are AI-Native, Not AI-Safe by Accident

One of the strongest conclusions in the source report is that AI is not only destroying roles. It is creating new demand in roles such as:

  • AI drug discovery engineer,
  • AI strategy roles inside life sciences,
  • algorithm-audit and model-governance work,
  • AI-enabled data translation,
  • and automation-heavy manufacturing design.

The source explicitly notes that AI drug discovery engineers are growing at 40-50% annually and remain undersupplied.

That is a critical distinction. The safest work in pharma is no longer just seniority or domain tenure. It is work that sits one layer above the model:

  • designing the workflow,
  • auditing the output,
  • integrating science with platform capability,
  • and taking accountability for consequential decisions.

The Structural Conclusion: Pharma Is Not Being Replaced, but Its Labor Model Is Being Repriced

The pharma and biotech story is not “AI takes over science.” It is narrower and more important than that.

AI is repricing the information layer of the industry.

That includes:

  • safety-case handling,
  • data operations,
  • document production,
  • candidate prioritization,
  • standard computational analysis,
  • and repetitive commercial workflow.

The parts that stay human are the parts where error costs are high and ambiguity cannot be cleanly reduced:

  • translational judgment,
  • clinical safety decisions,
  • wet-lab troubleshooting,
  • regulatory strategy,
  • manufacturing exception handling,
  • and leadership across science, compliance, and business.

In other words, AI is not replacing pharma. It is compressing the number of people needed to move information through pharma, while increasing the leverage of people who still have to decide what the information means.

Sources

  • Grand View Research, Pharmaceutical Market Report
    https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report
  • Precedence Research, Artificial Intelligence in Drug Discovery Market
    https://www.precedenceresearch.com/artificial-intelligence-in-drug-discovery-market
  • BioSpace, AI in Drug Discovery Market Size
    https://www.biospace.com/press-releases/artificial-intelligence-ai-in-drug-discovery-market-size-expected-to-reach-usd-16-52-billion-by-2034
  • Axis Intelligence, AI Drug Discovery 2026
    https://axis-intelligence.com/ai-drug-discovery-2026-complete-analysis/
  • McKinsey, How Pharma Is Rewriting the AI Playbook
    https://www.mckinsey.com/industries/life-sciences/our-insights/the-synthesis/how-pharma-is-rewriting-the-ai-playbook-perspectives-from-industry-leaders
  • Eularis, Reskilling in the AI Era for Pharma Professionals
    https://eularis.com/reskilling-in-the-ai-era-for-pharma-professionals/
  • PharmTech, Industry Outlook 2026: AI and Smart Factories
    https://www.pharmtech.com/view/from-ai-to-smart-factories-how-pharma-is-preparing-for-2026
  • PharmaVoice, 2026: AI Shifts from Analysis to Action
    https://www.pharmavoice.com/spons/2026-the-year-ais-role-in-pharma-shifts-from-analysis-to-action/806868/
  • PMC, AI in Pharmacovigilance
    https://pmc.ncbi.nlm.nih.gov/articles/PMC12317250/
  • IntuitionLabs, AI in Pharmacovigilance
    https://intuitionlabs.ai/articles/ai-pharmacovigilance-adverse-event-detection-gvp
  • GlobeNewswire, Recursion Q4 2025 Results
    https://www.globenewswire.com/news-release/2026/02/25/3244408/0/en/recursion-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update.html
  • BusinessWire, Multiply Labs 74% Cost Reduction
    https://www.businesswire.com/news/home/20250821262990/en/Robotics-Transforms-Cell-Therapy-Multiply-Labs-Drives-Staggering-74-Cost-Reduction-Unlocking-Global-Patient-Access
  • Universal Robots, Multiply Labs Case Study
    https://www.universal-robots.com/news-and-media/news-center/robotics-transforms-cell-therapy/
  • Veeva Systems, Announcing Veeva AI
    https://www.veeva.com/resources/announcing-veeva-ai/
  • IQVIA, IQVIA and Veeva Partnerships
    https://www.iqvia.com/newsroom/2025/08/iqvia-and-veeva-announce-long-term-clinical-and-commercial-partnerships
  • Applied Clinical Trials, Generative AI Transforms Clinical Study Reports
    https://www.appliedclinicaltrialsonline.com/view/generative-ai-transforms-clinical-study-report-development
  • AlphaLife Sciences, AI Medical Writing
    https://alphalifesci.com/products/auroraprime-rma/medical-writing
  • Clinion, CSR Automation
    https://www.clinion.com/csr-automation/
  • Xtalks, Top Pharma and Healthcare Companies by Employees 2025
    https://xtalks.com/top-20-largest-pharma-and-healthcare-companies-in-2025-by-number-of-employees-4289/
  • CB Insights, Pharma AI Readiness Index 2025
    https://www.cbinsights.com/research/ai-readiness-index-pharma-2025/
  • IMD, Future Readiness Indicator: Pharmaceuticals 2025
    https://www.imd.org/future-readiness-indicator/home/pharmaceuticals-2025/
  • IntuitionLabs, Top AI Patent Leaders in Pharma
    https://intuitionlabs.ai/articles/pharma-ai-patent-leaders
  • Tempus, Q3 2025 Results
    https://www.tempus.com/news/tempus-reports-third-quarter-2025-results/
  • Deep6 AI
    https://deep6.ai/life-sciences/
  • ISPOR, Top 10 HEOR Trends
    https://www.ispor.org/heor-resources/top-10-heor-trends
  • Precedence Research, HEOR Services Market
    https://www.precedenceresearch.com/health-economics-and-outcomes-research-services-market
  • PharmExec, AI in Pharma: Where, When, and How
    https://www.pharmexec.com/view/ai-where-when-how-executives-considering-it
  • DrugPatentWatch, AI in Pharmaceutical Patent Strategy
    https://www.drugpatentwatch.com/blog/ais-breakthrough-applications-in-pharmaceutical-patent-analysis-and-strategy/
  • IntuitionLabs, Veeva Link KOL Guide
    https://intuitionlabs.ai/articles/veeva-link-kol-identification-medical-affairs
  • Freyr Solutions, freya fusion
    https://www.freyafusion.com/
  • Frontiers, Advancing AAV Vector Manufacturing
    https://www.frontiersin.org/journals/molecular-medicine/articles/10.3389/fmmed.2025.1709095/full
  • Nature, Systematic Discovery of CRISPR-Boosted CAR-T
    https://www.nature.com/articles/s41586-025-09507-9
  • NEJM, Base-Edited CAR7 T Cells
    https://www.nejm.org/doi/full/10.1056/NEJMoa2300709
  • SynBioBeta, AI Reshaping Protein Engineering
    https://www.synbiobeta.com/read/folding-the-future-how-ai-is-reshaping-protein-engineering
  • Pharmaceutical Commerce, Cold Chain AI
    https://www.pharmaceuticalcommerce.com/view/pharmaceutical-cold-chain-logistics-artificial-intelligence
  • Standard Bots, Pharmaceutical Robots 2025
    https://standardbots.com/blog/pharmaceutical-robots
  • Clinical Leader, Navigating FDA AI Systems
    https://www.clinicalleader.com/doc/navigating-fda-s-new-ai-systems-practical-tips-for-regulatory-success-0001
  • SR Analytics, AI in the Pharmaceutical Industry 2026
    https://sranalytics.io/blog/ai-in-pharmaceutical-industry/